Novel Antibody Constructs and Alternative Scaffolds
Engineering, New Targets and Lead Selection
4-5 November 2013
Novel Antibody Constructs and Alternative Scaffolds is a 1 ½ day conference with presentations, breakout discussions and excellent opportunities for networking. It features identification of new targets and phage display for antibody lead selection. It also includes scaffolds for novel products such as Fc fusion proteins, and focuses strongly on bi-specific antibody products from a variety of platforms, with emphasis on product properties such as half-life, stability, enhanced targeting, and payload capture. It covers targets such as GPCRs, EGFR and VEGF and additional cellular signaling and cancer targets, and includes updates on the novel products BiTe, TRAIL mimetics, Anticalins, and DARPins.
Doing It the Other Way Round: Using High-Throughput Human Monoclonal Antibody Generation to Identify New Drug Targets
Stefan Dübel, Ph.D., Biotechnology and Bioinformatics, Institute of Biochemistry, Technische Universität Braunschweig
Deep Sequencing of Phage Display Panning Output Pools to Guide Antibody Lead Selection
Stefan Ewert, Ph.D., Senior Investigator, Biologics, Novartis A.G.
Controlling Cellular Signaling with Ultraspecific Binding Proteins
Shohei Koide, Ph.D., Professor, Biochemistry and Molecular Biology, University of Chicago
Isolation and Optimization of Novel Anti-GPCR Antibodies
David Lowe, Ph.D. Fellow, R&D, Antibody Discovery and Protein Engineering, MedImmune LLC
Hexavalent TRAIL-Receptor-Agonists with Enhanced Therapeutic Properties: Underlying Engineering Concept and in vivo Activity Profile
Oliver Hill, Ph.D., Vice President, Molecular Biology, Apogenix GmbH
Improving PK and Cholesterol Lowering by A pH-Sensitive Anti-PCSK9-Antibody
Javier Chaparro-Riggers, Associate Research Fellow, Protein Engineering, Rinat, Pfizer Inc.
Anticalins: A Versatile Non-Ig Scaffold for the Design of Bifunctional Biotherapeutics
Arne Skerra, Professor, TU Munich & Co-Founder, Pieris A.G.
Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange
Janine Schuurman, Ph.D., Director, Strategic Research, Genmab A/S
Engineering Bispecificity into a Single Albumin-Binding Domain Aimed for Drug Targeting and in vivo Half-Life Extension
Johan Nilvebrant, Ph.D., Post-Doctoral Researcher, Protein Technology, Royal Institute of Technology, AlbaNova University Center, Stockholm
Engineering Stable Bispecific Antibodies in the Final Therapeutic Format
Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab LLC
F-star: Advancing Novel Bispecific Antibody Biologics in Oncology
John Haurum, CEO, F-star
Bi-Specific Antibody Derivatives that Bind Cell Surface Targets and Capture Payloads
Ulrich Brinkmann, Ph.D., Senior Principal Scientist, Pharma Research and Early Development (pRED), Large Molecule Research, Roche Penzberg
Human Bispecific Antibodies with a Common Light Chain: Combining Superior Functionality and Developmental Reliability in the Well-Established Full Length IgG Format
Ton Logtenberg, Ph.D., CEO, Merus BV
Designing Receptor Binding Proteins with Highly Potent Biological Function
Andreas Plückthun, Ph.D., Director and Professor, Biochemistry, University of Zurich
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Luis Borges, Ph.D., Scientific Director, Amgen, Inc.